S. Barrett

发表

The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.

A. Doherty, J. Warmus, A. Bridges, 2008, Bioorganic & medicinal chemistry letters.

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

J. Warmus, J. Sebolt-Leopold, Chunhong Yan, 2004, Nature Structural &Molecular Biology.

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

Alan R. Saltiel, A. Bridges, W. Leopold, 1999, Nature Medicine.

4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase.

Daniel F Ortwine, J. A. Spicer, W. Denny, 2007, Journal of medicinal chemistry.

2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles-O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase).

J. Warmus, A. Bridges, W. Leopold, 2008, Bioorganic & medicinal chemistry letters.

Improved homology modeling of the human & rat EP4 prostanoid receptors

S. Barrett, M. Holt, M. I. Morano, 2019, BMC Molecular and Cell Biology.

Corrigendum: Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

J. Warmus, J. Sebolt-Leopold, Chunhong Yan, 2005, Nature Structural &Molecular Biology.

KMN-159, a novel EP4 receptor selective agonist, stimulates osteoblastic differentiation in cultured whole rat bone marrow.

S. Barrett, T. Owen, M. I. Morano, 2020, Gene.

CI-1017, a functionally M1-selective muscarinic agonist: design, synthesis, and preclinical pharmacology.

M. Emmerling, S. Barrett, H. Tecle, 2000, Pharmaceutica acta Helvetiae.

SN2′ Substitutions of 1,3-Dichloropropenes with the Functionalized Copper-Zinc Reagents RCu(CN)ZnX

S. Barrett, P. Knochel, Guan Huai, 1990 .

New Route to 4-Aminocyclopent-2-en-1-ols: Synthesis and Enantioselective Rearrangement of 4-Amino-substituted Cyclopentene Oxides

S. Barrett, P. O’Brien, H. C. Steffens, 2000 .

SN2′ Substitutions of 1,3-Dichloropropenes with the Functionalized Copper-Zinc Reagents RCu(CN)ZnX.

S. Barrett, P. Knochel, J. Gage, 1991 .

EFFICIENT SYNTHESIS OF EXO-1-AZABICYCLO[2.2.1]HEPTAN-3-OL

S. Barrett, H. Tecle, J. Jaén, 1997 .

Efficient Synthesis of exo‐1‐Azabicyclo(2.2.1)heptan‐3‐ol.

S. Barrett, J. Jaén, B. Caprathe, 1997 .

In vitro and in vivo evaluation of the subtype-selective muscarinic agonist PD 151832.

M. Brann, S. Barrett, J. Jaén, 1995, Life sciences.

Difluoromethylene at the γ-Lactam α-Position Improves 11-Deoxy-8-aza-PGE1 Series EP4 Receptor Binding and Activity: 11-Deoxy-10,10-difluoro-8-aza-PGE1 Analog (KMN-159) as a Potent EP4 Agonist.

S. Barrett, F. Ciske, T. Owen, 2019, Journal of medicinal chemistry.

Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms.

S. Barrett, D. T. Dudley, H. Tecle, 2007, Arthritis and rheumatism.

Z-(±)-1-azabicyclo[2.2.1]heptan-3-one, O-(3-aryl-2-propynyl) oximes as potential m1-subtype selective muscarinic agonists

S. Barrett, T. Mirzadegan, J. Jaén, 1995 .

Discovery of a series of 2-(1H-pyrazol-1-yl)pyridines as ALK5 inhibitors with potential utility in the prevention of dermal scarring.

Mostofa A Hena, B. Finzel, R. Gilbertsen, 2012, Bioorganic & medicinal chemistry letters.

Design and synthesis of m1-selective muscarinic agonists: (R)-(-)-(Z)-1-Azabicyclo[2.2.1]heptan-3-one, O-(3-(3'-methoxyphenyl)-2-propynyl)oxime maleate (CI-1017), a functionally m1-selective muscarinic agonist.

M. Brann, S. Barrett, H. Tecle, 1998, Journal of medicinal chemistry.

Improved homology modeling of the human & rat EP4 prostanoid receptors

S. Barrett, M. Holt, M. I. Morano, 2019, BMC Molecular and Cell Biology.

Pantolactams as androgen receptor antagonists for the topical suppression of sebum production.

Danielle E. Dettling, V. Shanmugasundaram, S. Barrett, 2011, Bioorganic & medicinal chemistry letters.

The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.

J. Warmus, J. Sebolt-Leopold, A. Saltiel, 2008, Bioorganic & medicinal chemistry letters.